The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
For additional information please call: 1-800-718-1021
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Ste-Foy, Quebec, Canada
Pfizer Investigational Site
Parktown, Johannesburg, South Africa
Change in LDL-C and HDL-C
Other lipid variables
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Bloemfontein, South Africa
Pfizer Investigational Site
Cape Town, South Africa